<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9608">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02981862</url>
  </required_header>
  <id_info>
    <org_study_id>2016-A01085-46</org_study_id>
    <nct_id>NCT02981862</nct_id>
  </id_info>
  <brief_title>Validation of the Method &quot;CaptHPV&quot; for the Diagnosis of Human Papillomavirus Associated Infiltrating Carcinomas</brief_title>
  <acronym>CaptHPV</acronym>
  <official_title>Monocentric Study of Validation of the Method &quot;CaptHPV&quot; for the Diagnosis of Human Papillomavirus Associated Infiltrating Carcinomas From a Biological Specimen.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Cancérologie de Lorraine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut de Cancérologie de Lorraine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current project is based on the assumption that a diagnosis of human papillomavirus
      associated Infiltrating Carcinomas can be made from a blood sample for patient with Cervical
      Cancer, Vulvar Cancer, Anal Cancer or Oropharynx Cancer at any stage of the disease and
      including surgical treatment for the small tumors.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessement of CaptHPV method</measure>
    <time_frame>1 day</time_frame>
    <description>The diagnostic value of the serum marker provided by the method CaptHPV will be assessed in sensitivity and specificity to results of histological and virological analyzes of a sample tumor.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Cervical Cancer</condition>
  <condition>Vulvar Cancer</condition>
  <condition>Anal Cancer</condition>
  <condition>Oropharynx Cancer</condition>
  <arm_group>
    <arm_group_label>CaptHPV method</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CaptHPV method</intervention_name>
    <description>10 ml of blood sample will be made before the beginning of all treatment. This blood sample will be sent to the CERBA Laboratory for analysis.
In parallel, a standard anatomopathological and virological analysis will be carried out from a biopsy or from a tumor sample by the Tumor Biology Unit at Lorraine Institute of Oncology
The results of both analyzes will be compared blindly.</description>
    <arm_group_label>CaptHPV method</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;18 years

          -  Patient with cervical cancer or vulvar cancer or anal cancer or oropharynx cancer

          -  Patient naive of any treatment for this pathology

          -  Patient capable and willing to follow all procedures of the study in accordance with
             the stydy

          -  Ability to provide an informed written consent form

          -  Affiliation to a social security system

        Exclusion Criteria:

          -  Patients who have already undergone surgical treatment leading to complete removal of
             the lesions or who have started treatment with radiotherapy and / or chemotherapy

          -  Patient whose health status contraindicates a blood sample of 10 ml,

          -  Absence of informed written consent form

          -  Pregnant or breast feeding females

          -  Patients deprived of liberty or under supervision
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>SASTRE-GARAU Xavier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Cancérologie de Lorraine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>GILLON Véronique</last_name>
    <phone>+ 33 3 83 59 86 08</phone>
    <email>v.gillon@nancy.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>FERNANDES Laurinda</last_name>
    <phone>+ 33 3 83 59 84 87</phone>
    <email>l.fernandes@nancy.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut de Cancérologie de Lorraine</name>
      <address>
        <city>Vandoeuvre-lès-Nancy</city>
        <zip>54519</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SASTRE-GARAU Xavier, MD</last_name>
      <phone>+ 33 3 83 59 84 83</phone>
      <email>x.sastregarau@nancy.unicancer.fr</email>
    </contact>
    <contact_backup>
      <last_name>CHARRA-BRUNAUD Claire, MD</last_name>
      <phone>+ 33 3 83 59 84 87</phone>
      <email>c.brunaud@nancy.unicancer.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 3, 2017</lastchanged_date>
  <firstreceived_date>November 30, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HPV infection</keyword>
  <keyword>Blood sample</keyword>
  <keyword>Biopsy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Vulvar Neoplasms</mesh_term>
    <mesh_term>Anus Neoplasms</mesh_term>
    <mesh_term>Oropharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
